Incidence of sustained ocular hypertension using prepackaged versus freshly prepared intravitreal bevacizumab for neovascular age-related macular degeneration

Philip P. Storey, Vincent Ho, Steven Yeh, Sahitya Reddy, Natalie Hsiao Fang-Yen, Edward Pequignot, Benjamin E. Leiby, Mitchell Fineman, Sunir Garg, G. Baker Hubbard, Jason Hsu

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Purpose: To compare the incidence of sustained ocular hypertension (OHT) after intravitreal injections of prepackaged versus freshly prepared bevacizumab monotherapy for the treatment of neovascular age-related macular degeneration. Methods: Charts of 1,216 patients with neovascular age-related macular degeneration receiving intravitreal bevacizumab monotherapy at 2 retina practices using different preparations of bevacizumab between January 1, 2009, and December 31, 2011, were reviewed. Primary outcome was incidence of sustained OHT, defined as intraocular pressure .25 mmHg with an increase 6 from baseline on 2 consecutive visits or requiring treatment. Results: A total of 6,479 injections in 740 eyes of 634 patients were included and 14 eyes (0.81% incidence per eye-year) developed sustained OHT. For eyes receiving prepackaged bevacizumab, 10 of 339 eyes (1.39% incidence per eye-year) developed sustained OHT compared with 4 of 401 eyes (0.39% incidence per eye-year) receiving freshly prepared bevacizumab, giving an incidence rate ratio of 3.55 (95% confidence interval, 0.93-13.49; P = 0.063). All eyes that developed sustained OHT achieved intraocular pressure control with observation or topical therapy alone. Conclusion: Incidence of sustained OHT after intravitreal bevacizumab is low. We found a trend toward higher rates of sustained OHT with prepackaged bevacizumab although this difference was not statistically or clinically significant.

Original languageEnglish (US)
Pages (from-to)1992-2000
Number of pages9
JournalRetina
Volume35
Issue number10
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Keywords

  • Age-Related Macular Degeneration
  • Bevacizumab
  • Choroidal Neovascularization
  • Glaucoma
  • Intravitreal Injection
  • Ocular Hypertension
  • Vascular Endothelial Growth Factor.

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Incidence of sustained ocular hypertension using prepackaged versus freshly prepared intravitreal bevacizumab for neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this